Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now


Isis trading halts as FDA reviews key drug’s risks

Drug developer Isis Pharmaceuticals Inc. and partner Genzyme said Thursday ray ban sunglasses outleta panel of advisers to the Food and Drug Administration had voted 9 to 6 to recommend approval of Kynamro, for treating patients genetically predisposed to have sky-high LDL, or bad cholesterol.

Approval had looked far from certain, given recent questions about the experimental drug’s links to cancer. But the companies said that the advisory cheap ray banspanel decided there was sufficient data on the drug’s safety and effectiveness to allow sales of Kynamro. If approved, Kynamro will be the first Isis drug to reach market. The FDA is not bound to follow recommendations of its advisers, but usually does so.

Just Tuesday, the advisers had posted information on the FDA’s website noting that in recent patient studies, 23 patients getting Kynamro developed ray ban for saletumors and three of them died, while only two patients getting a placebo developed tumors. The advisory panel on endocrinology and metabolic drugs also noted liver and blood vessel cancers were seen in earlier tests of the drug conducted on mice.